NCT04331080View on ClinicalTrials.gov

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

May 26, 2022

Study Completion Date

May 26, 2022

Conditions
MammoplastyScarringScarBreast Reconstruction
Interventions
DRUG

Granexin® gel 100 μM

Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

DRUG

Granexin® gel 200 μM

Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

DRUG

Vehicle gel

Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

Trial Locations (11)

10021

Luxurgery, New York

27157

Wake Forest Baptist Hospital - Plastic and Reconstructive Surgery, Winston-Salem

33144

Ibrahim H. Amjad, MD, PA, West Miami

33166

Universal Axon Clinical Research, Doral

33176

Miami Plastic Surgery, Miami

52807

Iowa Plastic Surgery, Davenport

60611

Northwestern University - Feinberg School of Medicine - Division of Plastic & Reconstructive Surgery, Chicago

77388

Integrated Aesthetics, Spring

84132

University of Utah, Salt Lake City

90048

Private Clinic- David Kulber, Los Angeles

91105

Pasadena Surgeons, Pasadena

All Listed Sponsors
lead

Xequel Bio, Inc.

OTHER

NCT04331080 - A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery | Biotech Hunter | Biotech Hunter